Skip to Main Content

“BakerHostetler LLP has the depth within their organization to successfully achieve the desired results of their clients and to protect their interests.”

— U.S. News & Best Lawyers "Best Law Firms"

Our national and interdisciplinary Emerging Companies and Venture Capital team provides full life-cycle counsel to emerging companies – from formation to funding and growth to exit by sale or initial public offering (IPO) – and the corporate and institutional investors that invest in them. With the experience of more than 1,000 attorneys across 18 offices, we deliver precise, timely and relevant counsel to companies and investors on a pragmatic and cost-effective basis.


  • Represented the lead venture investor in a $100 million Series D Preferred stock financing by an artificial intelligence (AI) and robotics technology company.
  • Represented a medical device company in its $40 million Series A preferred stock
  • Represented the lead venture investor in a $90 million investment in the Series E
    preferred stock financing of a virtual pharmacy technology company.
  • Represented an electric vertical takeoff-and-landing company in more than $800 million in equity and debt financings.
  • Represented one of the lead venture investors in a $480 million Series F preferred stock
    financing by a leading AI data engine, application and evaluation technology company.
  • Represented an enterprise software as a service (SaaS) company in connection with more than $210 million in primary and secondary equity and debt financings.
  • Represented the lead venture investor in a $65 million Series B-1 preferred stock
    financing by an aerospace technology company.
  • Represented a sustainable agriculture company in connection with more than $250 million in debt and equity financings and licensing transactions.
  • Represented the lead venture investor in a $200 million investment in a leading AI
  • Represented an Internet of Things and cloud-based water efficiency company in connection with more than $25 million in equity and debt financings, as well as its international strategic partnerships and licensing transactions.
  • Represented an international buyer in its more than $1 billion bid to acquire a U.S.-based
    media company.
  • Represented a leading enterprise SaaS company in its sale to a large European software
  • Represented a cancer therapeutics company in its $400 million sale to a global biopharmaceutical company.
  • Represented a medical device company in its $350 million sale transaction.
  • Represented a web-based analytics company in its IPO and follow-on offerings.

Featured Insights